ADENOSQUAMOUS CARCINOMA OF THE BREAST: A RARE METAPLASTIC NEOPLASM WITH DISTINCT HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL FEATURES
Main Article Content
Keywords
Adenosquamous carcinoma, metaplastic breast carcinoma, triple-negative, squamous differentiation, immunohistochemistry, Ki-67, breast cancer.
Abstract
Adenosquamous cell carcinoma of the breast is one of the rare and aggressive types of metaplastic breast carcinoma, which has a squamous differentiation and biphasic glandular. ASC is less than 1% of all breast malignancies, and it is problematic about its diagnosis because it is morphologically similar to other subtypes of breast carcinomas.
Case Presentation: A 37-year-old woman presented with a noticeable lump in her right breast. Radiological imaging revealed a metabolically active lesion with regional lymphadenopathy, and histopathological examination confirmed ASC with both glandular and squamous components. Immunohistochemistry showed a triple-negative immunophenotype, with p40 positivity and CK7 expression, indicative of squamous differentiation. The Ki-67 index was 70%, highlighting its high proliferative index.
Conclusion: ASC of the breast is a rare and aggressive neoplasm that presents great diagnostic and treatment problems. Its triple-negative nature requires chemotherapy because the targeted therapies are not effective. This case emphasises the importance of early diagnosis and multidisciplinary management.
References
2. Reis-Filho JS, Lakhani SR (2008) Breast cancer special types: why bother? The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland 216:394–398
3. Rakha EA, Tan PH, Varga Z, et al (2015) Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. British journal of cancer 112:283–289
4. Lakhani SR, Ellis IO, Schnitt S, et al (2012) WHO Classification of Tumours of the Breast.
5. McCart Reed AE, Kalaw E, Nones K, et al (2019) Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications. The Journal of pathology 247:214–227
6. Tavassoli FA (2003) World Health Organization classification of tumors. Pathology and genetics of tumors of the breast and female genital organs 97:
7. Altaf FJ, Mokhtar GA, Emam E, et al (2014) Metaplastic carcinoma of the breast: an immunohistochemical study. Diagnostic pathology 9:139
8. Hicks DG, Lester SC (2016) Expression Profiling, Oncotype DX Assay. Diagnostic pathology, diagnostic pathology: breast 2nd ed Amsterdam: Elsevier 478–81
9. Tse GM, Tan PH, Putti TC, et al (2006) Metaplastic carcinoma of the breast: a clinicopathological review. Journal of clinical pathology 59:1079–1083
10. Bishop JA, Teruya-Feldstein J, Westra WH, et al (2012) p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern pathology 25:405–415
11. Leibl S, Moinfar F (2005) Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol 58:700–704
12. Yerushalmi R, Woods R, Ravdin PM, et al (2010) Ki67 in breast cancer: prognostic and predictive potential. The lancet oncology 11:174–183
13. Kamra HT, Gadgil PA, Chaware SA, et al (2011) Acantholytic variant of squamous cell carcinoma of breast: a rare case report. ecancermedicalscience 5:214
14. McKinnon E, Xiao P (2015) Metaplastic carcinoma of the breast. Archives of pathology & laboratory medicine 139:819–822
15. Piscuoglio S, Ng CK, Geyer FC, et al (2017) Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. NPJ breast cancer 3:48
16. Weigelt B, Eberle C, Cowell CF, et al (2014) Metaplastic breast carcinoma: more than a special type. Nature Reviews Cancer 14:147–148
17. El Zein D, Hughes M, Kumar S, et al (2017) Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature. Clinical breast cancer 17:382–391
18. Zhang Y, Lv F, Yang Y, et al (2015) Clinicopathological features and prognosis of metaplastic breast carcinoma: experience of a major Chinese cancer center. PloS one 10:e0131409
19. Masuda H, Baggerly KA, Wang Y, et al (2013) Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clinical cancer research 19:5533–5540
20. Miettinen M, McCue PA, Sarlomo-Rikala M, et al (2014) GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. The American journal of surgical pathology 38:13–22
21. Ong CT, Campbell BM, Thomas SM, et al (2018) Metaplastic breast cancer treatment and outcomes in 2,500 patients: A retrospective analysis of a national oncology database. Annals of surgical oncology 25:2249
22. Wong W, Brogi E, Reis-Filho JS, et al (2021) Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. NPJ breast cancer 7:96
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Radhika Vashisth
HOD Pathology, FIMS hospital, Sonipat, Haryana
Dr Anil jain
HOD surgery, Medical Director, FIMS Hospital, Sonipat, Haryana
Dr Parveen kumar
Medical Director, Prabha eye Hospital, Narela, Delhi
Dr Sunny Jain
HOD, Oncology, FIMS hospital
Dr Sahil Dureja
Medical Officer, FIMS hospital
